Every 8-K that Tango Therapeutics Inc (TNGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TNGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNGX filings page.
Tango Therapeutics, Inc. expanded its at-the-market offering program for its common stock through Leerink Partners LLC as sales agent. The company previously registered an aggregate offering price of up to $100,000,000 under a prior prospectus supplement, of which approximately $64,389,566 of shares have been sold and approximately $35,610,434 remain unsold.
On August 11, 2026, Tango filed a new prospectus supplement covering shares of common stock with an aggregate offering price of up to $400,000,000, which includes the approximately $35,610,434 of unsold shares from the prior prospectus supplement. The prior prospectus supplement has been terminated, and any future sales, if any, will be made under the new prospectus supplement and the existing automatic shelf registration statement. Goodwin Procter LLP issued a legal opinion on the newly registered shares.
Tango Therapeutics, Inc. reported second-quarter 2026 results and provided clinical and corporate updates. Initial Phase 1/2 data showed vopimetostat plus daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival in MTAP-deleted, RAS-mutant pancreatic cancer, with a generally well-tolerated safety profile. The company is working with regulators and collaborator Revolution Medicines on a registrational plan and intends to present detailed data at the 2026 ESMO Congress.
As of June 30, 2026, Tango held $1.0 billion in cash, cash equivalents and marketable securities. For the quarter, research and development expenses were $37.2 million and general and administrative expenses were $22.6 million, leading to a net loss of $55.3 million, or $0.37 per share. The company strengthened its leadership with the appointment of Fatma Ocak as Chief Commercialization Officer and Robert Azelby as Chairman of the Board, and outlined multiple clinical milestones expected in the second half of 2026.
Tango Therapeutics amended an earlier disclosure to add the terms of a Separation Agreement with former Executive Chair Dr. Barbara Weber, whose employment and board roles ended effective August 3, 2026. The agreement was executed on August 6, 2026.
Dr. Weber is entitled to base-salary severance through December 31, 2026, paid in installments, and reimbursement of monthly COBRA premiums through the same date, conditional on not revoking the agreement. Equity terms include full acceleration of outstanding options and RSUs (subject to Compensation Committee approval) and extension of the post-termination exercise period for vested and accelerated options to the earlier of August 3, 2027 or each option’s original expiration. She will also receive a pro‑rata 2026 annual incentive, if earned based on company and individual performance, paid with other employees’ bonuses no later than March 15, 2027.
Tango Therapeutics, Inc. reports that Dr. Barbara Weber’s employment as Executive Chair ended on August 3, 2026, in accordance with her Amended and Restated Employment Agreement dated January 8, 2026, and that she is deemed to have resigned from all officer and board positions.
The company states that her resignation was not due to any disagreement regarding operations, practices or policies. Subject to Dr. Weber executing and not revoking a Separation Agreement, she is offered base-salary severance and COBRA reimbursement through December 31, 2026, acceleration of equity awards equal to 12 additional months of vesting, an extended stock option exercise period to the earlier of August 3, 2027 or the options’ original expirations, and a pro‑rated 2026 annual incentive payable no later than March 15, 2027. The company plans to file the Separation Agreement once it is fully effective and includes cautionary language regarding forward‑looking statements.
Tango Therapeutics, Inc. expanded its Board of Directors to seven members and appointed biopharmaceutical executive Robert Azelby as a Class II director, with a term running until the 2029 annual meeting of stockholders. The Board determined he is independent under Nasdaq listing standards and named him to the Compensation Committee and the Nominating and Corporate Governance Committee, effective June 23, 2026.
Under the non-employee director compensation program, he will receive a stock option for 35,910 shares at an exercise price of $27.97 per share, vesting monthly over three years, and an RSU award for 5,740 shares vesting annually over three years, along with cash retainers for Board and committee service. The accompanying press release highlights his three decades of oncology and commercial leadership and notes his appointment comes as Tango advances its investigational PRMT5 inhibitor vopimetostat toward potential late-stage development for MTAP-deleted cancers, including pancreatic cancer.
Tango Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 18,166,667 shares of common stock and pre-funded warrants to purchase up to 1,833,395 additional shares. The shares are priced at $30.00 each and the pre-funded warrants at $29.999 each, reflecting a $0.001 exercise price.
The company also granted underwriters a 30-day option to buy up to 3,000,009 additional shares. Tango estimates net proceeds of approximately $566.5 million, to be used for general corporate purposes, including research and development, pivotal trial expenses, commercialization preparation, and capital expenditures. Based on its current plan, it believes existing funds plus this offering will support operations into 2030.
Tango Therapeutics reported initial Phase 1/2 data for its PRMT5 inhibitor vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors in hard‑to‑treat cancers. In previously treated MTAP‑deleted, RAS‑mutant pancreatic cancer, vopimetostat plus daraxonrasib produced a 92% objective response rate in 12 evaluable patients and a 90% six‑month progression‑free survival rate, with all patients achieving disease control.
Three non‑small cell lung cancer patients on the same combination all responded. A separate vopimetostat plus zoldonrasib arm in pancreatic cancer showed a 52% objective response rate and 74% six‑month progression‑free survival in 27 evaluable patients, with 96% disease control. Safety across combinations was generally favorable, with mostly mild or moderate side effects and no treatment‑related grade 4 or 5 events or discontinuations.
Based on these results, Tango plans to advance the vopimetostat plus daraxonrasib regimen into Phase 3 development as a front‑line, chemotherapy‑free option for MTAP‑deleted pancreatic cancer, while exploring second‑line registration paths and broader development of its PRMT5 franchise.
Tango Therapeutics, Inc. held its 2026 annual stockholder meeting on June 4, 2026 in a virtual-only format. Of 144,242,271 common shares entitled to vote as of April 7, 2026, 131,198,081 shares were present or represented by proxy, representing 90.96% and establishing a quorum.
Stockholders elected Class II directors Malte Peters, M.D. (98,188,796 votes for; 17,623,596 withheld; 15,385,689 broker non-votes) and Mace Rothenberg, M.D. (92,476,172 for; 23,336,220 withheld; 15,385,689 broker non-votes), each to serve until the 2029 annual meeting.
They also ratified PricewaterhouseCoopers, LLP as independent registered public accounting firm for the year ending December 31, 2026 (131,097,992 for; 73,823 against; 26,266 abstain) and approved, on a non-binding advisory basis, compensation of named executive officers (113,915,877 for; 1,855,838 against; 40,677 abstain; 15,385,689 broker non-votes).
Tango Therapeutics reported first quarter 2026 results and highlighted progress in its oncology pipeline. The company ended March 31, 2026 with $379.8 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2028.
Collaboration revenue was $0 for the quarter, compared with $5.4 million a year earlier after the Gilead collaboration concluded. Research and development expenses were $33.5 million versus $36.4 million, while general and administrative expenses rose to $15.2 million from $11.5 million.
Net loss was $45.5 million, or $0.32 per share, compared with a net loss of $39.9 million, or $0.36 per share, in the prior-year period. The company reported encouraging early data from vopimetostat combination studies and outlined multiple 2026 clinical milestones. Two directors, Alexis Borisy and Kanishka Pothula, resigned without disagreements, and Sung Lee was appointed Lead Independent Director and chair of the Compensation Committee.
Tango Therapeutics, Inc. entered into a Separation Agreement and Release with former Chief Financial Officer Daniella Beckman on May 7, 2026, following the Board’s earlier decision that she would cease serving as CFO, principal accounting officer and principal financial officer effective April 15, 2026.
Under the agreement and her employment contract, Ms. Beckman will receive 12 months of severance pay at her current base salary, paid in installments, plus reimbursement of monthly COBRA premiums for up to 12 months. The company will also accelerate the vesting of her outstanding stock options and restricted stock units to reflect an additional 24 months of continued service from her May 1, 2026 employment end date and extend the post-termination stock option exercise period through August 31, 2026, in exchange for her signing a general release in favor of the company.
Tango Therapeutics announced several leadership changes and equity awards to support its late-stage oncology pipeline. The board decided that Daniella Beckman will step down as Chief Financial Officer, principal accounting officer and principal financial officer, effective April 15, 2026.
Effective the same date, Matthew Gall becomes Chief Financial Officer and principal financial officer under an employment agreement that includes an option for 240,000 shares and 40,000 restricted stock units, subject to time-based vesting and continued employment. Jessica Newcomb is appointed principal accounting officer, while a related press release highlights additional senior hires in development operations and corporate strategy to help advance vopimetostat toward potential regulatory approval in pancreatic cancer.
Tango Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided pipeline and corporate updates. Cash, cash equivalents and marketable securities totaled $343.1 million as of December 31, 2025, which the company expects will fund operations into 2028.
Collaboration revenue was $62.4 million for 2025, up from $30.0 million in 2024, mainly reflecting recognition of remaining Gilead deferred revenue. Research and development expenses declined to $132.2 million from $143.9 million, while net loss narrowed to $101.6 million, or $0.87 per share, from $130.3 million, or $1.19 per share. The company highlighted progress for lead PRMT5 inhibitor vopimetostat, plans for a pivotal 2L pancreatic cancer study in 2026, new combination collaborations, and leadership changes including a new CEO and Chief Regulatory Officer.
Tango Therapeutics, Inc. reported that its unaudited cash, cash equivalents and marketable securities totaled $343 million as of December 31, 2025, providing an early view of its year-end liquidity. The company announced a leadership transition in which Barbara Weber, M.D. retired and resigned as President and Chief Executive Officer effective January 8, 2026, and moved into the role of Executive Chair through December 31, 2026 to support an orderly handover.
On the same date, board member Malte Peters, M.D. was appointed President and Chief Executive Officer. In connection with his role, he received an option to purchase 1,650,000 shares of common stock and 350,000 restricted stock units, each subject to multi‑year vesting and continued employment. The company also furnished a press release and updated corporate presentation describing these changes.
Tango Therapeutics, Inc. entered into a new Sales Agreement with Leerink Partners LLC, establishing an at-the-market equity program under which it may sell up to $100,000,000 of its common stock from time to time. Shares may be sold through Leerink as sales agent in transactions deemed an “at the market offering” or in negotiated deals if authorized by the company. Tango will pay the agent a commission of up to 3.0% of the gross sales price of any shares sold and has provided customary indemnification rights.
The company also terminated its prior Open Market Sales Agreement with Jefferies LLC, under which it had similarly been able to sell up to $100,000,000 of common stock. The Jefferies agreement ends effective November 21, 2025, and Tango states it will not face termination penalties and will no longer offer or sell shares under the 2022 ATM program.
Tango Therapeutics (TNGX) furnished a press release covering its results of operations and financial condition for the quarter ended September 30, 2025, via an Item 2.02 Form 8‑K.
The press release is furnished, not filed, and appears as Exhibit 99.1. The report was signed by Chief Financial Officer Daniella Beckman.
Tango Therapeutics (TNGX) entered an underwriting agreement for a registered direct offering of 21,023,337 common shares and pre-funded warrants exercisable for up to 3,226,458 shares. Each share was sold at $8.66 and each pre-funded warrant at $8.659, with an exercise price of $0.001. All securities were sold by the company.
The company estimates net proceeds of approximately $197 million from the registered direct offering, expected to close on October 24, 2025, and plans to use the funds to advance its pipeline, working capital, and general corporate purposes. Pre-funded warrants are immediately exercisable, do not expire, and include beneficial ownership caps of 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ notice. Tango also agreed to a concurrent $15 million private placement of 1,732,101 shares at $8.66 per share. With these financings and existing cash, the company believes it can fund operations into 2028.
Tango Therapeutics (TNGX) filed an 8‑K disclosing preliminary liquidity and a clinical update. As of September 30, 2025, the company estimates it had $152.8 million in cash, cash equivalents and marketable securities. Management emphasized this figure is preliminary and unaudited and may change after quarter‑end closing procedures.
The company also made available a slide presentation with a clinical update from its ongoing Phase 1/2 trial of vopimetostat (formerly TNG462), furnished as Exhibit 99.1. The external auditor has not performed any review or assurance procedures on the preliminary data.
Tango Therapeutics, Inc. reported that Douglas Barry has resigned from his roles as Chief Legal and Compliance Officer and Corporate Secretary. He notified the board of directors on August 21, 2025, and his resignation will be effective as of September 12, 2025. The company states that he is leaving to pursue another opportunity.